Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer

HJ de Voogt, U Struder, Fritz Schröder, Jan Klijn, M de Pauw, R Sylvester

Research output: Contribution to journalArticleAcademicpeer-review

37 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)152-158
Number of pages7
JournalEuropean Urology
Publication statusPublished - 1998

Research programs

  • EMC 04-01-DD-01-01

Cite this